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DIETHYLPROPION ("Tenuate") has been shown to be useful in the treatment of
refractory obesity (Seaton et al., 1961). Appetite suppression with the standard
preparation is reported to last about four hours (Spielman, 1959) and the drug
must be taken at least three times daily. This paper reports the use of a long-
acting preparation of the drug, which need be taken only once a day. It is
marketed as "Tenuate Dospan" in which the active principle is incorporated
with a hydrophilic colloid, which expands in the intestine and allows a continuous
release of the drug. The advantage claimed, in addition to the virtual absence
of undesirable central nervous stimulation (Wilson and Long, 1960; Nash, 1960),
is that the sustained release tablet will provide hunger control for a full twelve
hours.
Diethylpropion (a-diethylaminopropionophenone) is closely related structurally
to amphetamine (B-aminopropylbenzene).
METHODS.
A double-blind cross-over technique was used. Patients with obesity who had
been referred on this account to the general medical or metabolic departments
of the Royal Victoria Hospital were considered for admission to the trial. Those
with serious associated disease were excluded, and the remainder were asked if
they wished to attend a special monthly clinic to help them lose weight. They
were offered the attraction of a number of new drugs which might help in the
treatment of their obesity.
They were fully examined at their first visit and a detailed family and dietary
history elicited. They were weighed in normal indoor clothes, without shoes,
by the same nurse on the same scales at each visit. (The scales are checked
monthly for accuracy.) All patients were interviewed by the dietician attached
to the Metabolic Clinic, and were given a standard 1100 calorie reduction diet
containing 100 G. of carbohydrate, or told to continue their existing regime if
they were already intended to consume less than 1100 calories on a recognised
schedule. The discussion of methods of weight reduction was limited to
encouragement to keep to the diet. The tablets were presented as an aid to weight
loss, with no mention of their method of action, or possible side effects. The
patients were not told that this was a double blind trial.
Those taking part in the trial were divided into two groups ("A" and "B")
at their first visit, according to a sequence constructed from a table of random
109numbers. Bottles, with detachable identification tags were available, containing
four weeks' supply of either diethylpropion tablets (75 mg.), or an identically
presented placebo. Each group commenced with one type of tablet, and after
four weeks the distribution was reversed. Patients were instructed to take one
tablet each morning before breakfast.
They were reviewed by one of us after four and eight weeks. No direct
enquiries were made about the patients' subjective impressions of the drug or
possible side effects. Only spontaneous complaints were noted. Neither the
patients, the doctors, the dietitians nor the nursing staff knew which tablets
contained the active preparation. A sealed envelope containing the manufacturer's
key to the identification tags was opened when the trial was completed. It was
then found that Group "A" had received the diethvlpropion in the first month,
and the placebo second; Group "B" had received the tablets in the opposite
order.
TABLE 1.
STATISTICAL DATA CONCERNING THE Two GROUPS.
Values are means, standard deviations and ranges.
DIFFERENCE OF THE MEANS.
GROUP A GROUP B Standard Level of
11 patients 11 patients deviation t significance
Age (years) - - 40 + 12.6 (17-59) ... 36 + 16.3 (13-56) ... 14.35 ... 0.28 ... 0.8>P>0.7
Height (inches) - 63 + 3.4 (59-68) ... 63 + 3.0 (59-70) ... 1.45 ... 0.11 ... P>0.9
Initial weight (lb.) - 223 + 32.8 (167-272)... 206 +28.8 (160-239) ... 26.50 ... 0.65 ... 0.6>P>0.
Standardweight(lb.) 144 +14.2(121-165) ... 144 +19.5(104-182) ... 7.30 ... 0.05 ... P>0.9
Per cent. overweight 54.8 + 14.5 (23-72) ... 43.6 +22.2 (22-84) ... 8.36 ... 1.36 ... 0.2>P>0.1
THE PATIENTS.
Twenty-two patients completed the trial out of thirty-eight who were initially
accepted.
A comparison of the two groups of patients "A" and "B" who completed the
two months' treatment is shown in Table 1. The groups, having been selected
at random, are comparable as regards age and height, and hence also standard
weight, which is derived from these (Tables of the Life Extension Institute of
New York). The mean percentage by which the patients in Group "A" exceed
their standard weight is not significantly greater than that of Group "B" and
neither are the slight differences in mean initial weight and height.
Nine in each group had a history of obesity exceeding ten years' duration:
six in Group "A" and five in Group "B" had made a previous attempt at dieting.
There was one male in each group, and seven of the women in each group were
married. The mothers in Group "A" had a total of thirty children, and those
in Group "B" twenty-two children. Only two patients out of the whole series
spontaneously complained of hunger as a possible cause of their obesity.
110There were six cases of maturity onset diabetes mellitus, already controlled by
restriction of carbohydrate. Six patients had angina of effort but in only three
was ischxmia apparent on the electrocardiogram, and none showed evidence of
fluid retention. One patient had been treated for several years with thvroid
extract for mild hvpothydroidism (confirmed by radio-iodine studies) but was
euthvroid prior to anid during the trial. One showed clinical and biochemical
featuires of mild adrenal virilism.
TABLE 2.
RESULTS OF Cioss-OvFR TRIAL OF DIETHYLPROPION.
NUMBER OF PATIENTS MEAN WEIGHT Loss IN LB.
1st month 2nid month 2 months
GROUP A diethylpropioni placebo combined
9.99 0.99 10.98
1st month 2nd month 2 months GROUP B placebo diethylpropion combined
2.54 2.0 4.54
RESULTS.
These are recorded in Table 2. The best results were achieved in those who
were treated first with diethylpropion, and these patients lost almost 10 lb. on
average in this month. The mean loss in one month on diethylpropion for the
whole series of twenty-two patients was almost 6 lb., which is significantly
greater than the mean loss on the placebo, which was 1.75 lb. (0.02>P>0.01). As
the drug was given under a "double blind" technique, this proves the effectiveness
of the long-acting preparation of diethvlpropioni in the treatment of obesitv.
The "crossover" design allows assessment of the effect of the order of treatment.
When diethylpropion was given first, the weight loss in the first month was
significantly greater than the subsequent loss on the placebo (P<0.001). When
placebo was given first, the weight loss in the two periods was not significantly
different (0.7>P>0.6). Thus, the drug wzas no more effective than the placebo
when given in the second month.
The total weight loss in Group "A" after two months' treatment was not
significantly different from that in Group "B" (0.2>P>0.1). The greatest individual
weight loss during the two months was 40 lb., and one patient gained 9 lb. in
spite of the treatment. There was no correlation between loss of weight and age,
sex, height, initial weight or the amount by which the standard weight was
exceeded. The patients placed little emphasis on the effects of the tablets on their
appetite but eight volunteered that they felt less hungry while taking the
diethylpropion. Two stated that appetite was reduced equally by the two agents;
two others claimed that the placebo was more effective.
111SIDE EFFECrS.
These were not enquired after directly, and only spontaneous statements by
the patients of their own observations were noted. Only three of the total series
made any reference to alteration in their sleeping habits. One stated that there
was a very slight interference with sleep; the other two claimed increased
somnolence, all during the period on diethylpropion. Four patients mentioned
dryness of the mouth, accompanied by a salty taste but this was in no way
troublesome. There were no complaints of restlessness or headache. There was
no evidence of the development of schizophrenic symptoms or addiction to the
tablets. None of the group, including those known to have mild coronary artery
disease, experienced angina pectoris while on the trial. Treatment did not have
to be stopped in any case.
DiSCUSSION.
It is generally accepted that physiological weight loss can only be achieved
following a negative calorie balance. Most patients who are already obese are
unable to keep to a strict calorie limitation unaided. To encourage them to lose
weight high fat or high protein diets, bulking agents and tranquillizers with or
without psychotherapy have all been advocated, and shown to have some benefit.
Appetite suppression, which was discovered as a side-effect of the amphetamine
group of drugs, is a logical adjunct provided that the primary stimulant effect
of these substances on the central nervous system is not troublesome. Previous
reports and experience in the present trial have shown no evidence of such
stimulation with diethylpropion.
During the course of treatment there was no evidence of the development of
psychotic behaviour. The amphetamine-group of drugs are probably all equally
liable to cause this if abused. Addiction and schizophrenia are well recognised
following amphetamine (Connell, 1958; McConnell and Mcllwaine, 1961) and
a similar picture has been reported with phenmetrazine. There are, as yet, no
reports of addiction or psychosis due to diethylpropion or any of the newer
derivatives.
The mean weight loss in this series (5.99 lb.) is considerably greater than that
reported by Seaton et al., 1961 (2.58 lb.) after one month on diethylpropion.
We consider our group more representative of obesity in general, as only about
half would fall within their definition of "refractory" obesity (failure to respond
to dietary instructions during the previous year). The results in the first month
(9.99 lb.) are also superior to those reported by Briggs et al. (1961) in a more
comparable group, taking phenmetrazine hydrochloride (6.5 lb.). Stevens (1961)
reports a trial of a long-acting preparation of diethylpropion 60 mg. daily, which
gave an average weight loss on the active tablet of 1.9 lb. in one month. He
suggests that the dose should be slightly higher and the considerably better results
in our own series confirm the effectiveness of 75 mg. daily. We would not advise
further increase in dosage, as this may increase the liability to side effects.
Diethylpropion in long acting form was considerably less effective when given
following a month on placebo. Jaffe (1961), in a trial in general practice, found
112that weight loss during the first two months of a six-months period was greater
than subsequently and this aspect is also well illustrated by the results of Seaton
et al. (1961), where very little weight was lost after the first month. It would
seem wisest to recommend the use of anoretic drugs of this type in intermittent
courses of a few weeks' duration.
One aspect of the treatment of simple obesity is the extremely high incidence
of defaulters (sixteen out of thirty-eight in the present series). This makes a large
series difficult to accumulate, and is probably a further example of the general
mental attitude of many who allow themselves to become overweight.
The price of one month's treatment with "Tenuate Dospan" is 1ls. 2d.
SUMMARY.
A double-blind cross-over trial of diethylpropion (in a long-acting preparation)
in the treatment of simple obesity in conjunction with a low calorie diet, is
described.
The drug in this form is effective and without side effects.
Diethylpropion caused the greatest weight loss when it was given at the
commenicement of the trial. It was considerably less effective when administered
after a month's treatment with a placebo. For this reason it is recommended
that its clinical use should be restricted to short intermittent courses.
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